Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1419878 | 0.81 | IDO1 (0.41) | IDO1TDO2CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL2794399 | 0.81 | PARP1 (0.40) | IDO1TDO2CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL7756004 | 0.81 | IDO1 (0.38) | IDO1TDO2CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL933432 | 0.81 | SLC18A3 (0.41) | IDO1TDO2CYP2C19TGM2LMNA | |
| SCHEMBL2797594 | 0.81 | PARP1 (0.40) | IDO1TDO2CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL2794393 | 0.81 | PARP1 (0.40) | IDO1TDO2CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL2169566 | 0.81 | ALDH1A1 (0.44) | IDO1TDO2ALDH1A1GAAMAPT | |
| SCHEMBL24786374 | 0.78 | SMN1; SMN2 (0.41) | IDO1TDO2ALDH1A1SMN1; SMN2TGM2 | |
| SCHEMBL2170246 | 0.77 | CYP2C19 (0.41) | CYP2C19SMN1; SMN2TGM2LMNAHTR2A | |
| SCHEMBL28595236 | 0.77 | HDAC4 (0.40) | IDO1TDO2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| CN-102203089-A | N-sulfonylamino polycyclic pyrazolyl compounds | ELAN PHARM INC | 2011-09-28 | — | — | CN | disclosed |
| EP-2346863-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | Elan Pharmaceuticals Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010028213-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028213-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | PSEN1, PSEN2, SULT1E1 | IDO1 1839/4885TDO2 3934/4885CYP2C19 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.